Please login to the form below

Not currently logged in
Email:
Password:

atomoxetine

This page shows the latest atomoxetine news and features for those working in and with pharma, biotech and healthcare.

Lilly axes 3,500 jobs in $500m-a-year cost-cutting drive

Lilly axes 3,500 jobs in $500m-a-year cost-cutting drive

Strattera (atomoxetine) and erectile dysfunction therapy Cialis (tadalafil).

Latest news

  • Shire launches long-acting ADHD drug Intuniv in UK Shire launches long-acting ADHD drug Intuniv in UK

    It is also the first alternative to Eli Lilly's non-stimulant ADHD therapy Strattera (atomoxetine) in Europe, providing another option for the approximately 10% of people with the condition who

  • Lilly feels effects of Cymbalta competition Lilly feels effects of Cymbalta competition

    to $588m and attention-deficit hyperactivity disorder (ADHD) drug Strattera (atomoxetine) brought in $201m, up 23 per cent.

  • Scotland first in UK to back Pfizer's Inlyta Scotland first in UK to back Pfizer's Inlyta

    month - along with Roche's Lucentis (ranibizumab) for pathologic myopia and Eli Lilly's attention deficit hyperactivity disorder (ADHD) therapy Strattera (atomoxetine).

  • Lilly’s Strattera wins new adult ADHD licence in UK Lilly’s Strattera wins new adult ADHD licence in UK

    The Medicines and Healthcare Products Regulatory Agency (MHRA) granted authorisation to expand the indication of Strattera (atomoxetine) to initiate treatment of ADHD in adults, where pre-existing symptoms during childhood can

  • Therapy focus: ADHD

    The most commonly prescribed non-stimulant is atomoxetine. It is believed to work by increasing the amount of noradrenaline (one of the brain's chemical messengers), which helps manage the symptoms ... The most common side effects of atomoxetine are

More from news
Approximately 1 fully matching, plus 8 partially matching documents found.

Latest Intelligence

  • Challenging perceptions Challenging perceptions

    These classes were methylphenidate-based products like Johnson &Johnson's Concerta (methylphenidate hydrochloride) and Lilly's non-stimulant Strattera (atomoxetine).

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Synergy Vision

Synergy Vision believe in delivering medical communications that make a difference to healthcare professionals and patients. Our synergy of pharma...

Latest intelligence

Theresa Heggie
Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe
Theresa Heggie talks about the biotech’s 16-year path to market, and the promise of its ‘gene silencing’ medicines...
patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...

Infographics